Skip to content

Doubleblinded RCT of the Omnilux on Lower Extremity Surgical Wounds Left to Heal by Second Intention

Doubleblinded, Randomized, Controlled Trial to Study the Effect of Omnilux Light Emitting Diode on Wound Healing Following Lower Extremity Surgical Wounds Left to Heal by Second Intention

Status
Terminated
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02383056
Enrollment
14
Registered
2015-03-09
Start date
2012-12-31
Completion date
2017-11-30
Last updated
2019-05-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Wound

Keywords

wound, secondary intention healing, lower extremity

Brief summary

The goal of the study is to evaluate the effectiveness of the light-emitting diode (LED) in promoting healing of the wound on lower leg as a result of surgery. Wounds on the lower leg heal more slowly than wounds on the head and neck; they can also remain deep red for six months to one year. Doctors usually allow a lower leg surgical wound to heal by itself, without stitches or other additional treatment. This is because leg wounds do not hold stitches well and stitches could cause other problems. A major drawback of allowing a surgical wound on the lower leg to heal by itself is the long healing time that can often take months. The investigators wish to evaluate if the LED light treatment of the surgical wound will improve the healing of your wound. In order to test if leg wounds heal faster after treatment with LED, half of the patients in the study will receive the LED (Group 2) and half will not receive treatment with LED but will receive a sham light treatment (Group 1). Essentially, a sham light treatment refers to regular light (not LED) exposure for 20 minutes. The sham light comes from the same device as the treatment light (Omnilux machine) however, this light has no anticipated effects on wound healing and is used simply to reduce the amount of bias that sometimes complicates the results of these studies. There is no added risk or benefit for the patients in the control group exposed to the sham light. Both groups will receive the standard care of wounds on the lower extremity.

Detailed description

Group 2 of this study will receive the LED and half will not receive treatment with LED but will receive a sham light treatment (Group 1). Essentially, a sham light treatment refers to regular light (not LED) exposure for 20 minutes. The sham light comes from the same device as the treatment light (Omnilux machine) however, this light has no anticipated effects on wound healing and is used simply to reduce the amount of bias that sometimes complicates the results of these studies. There is no added risk or benefit for the patients in the control group exposed to the sham light. Both groups will receive the standard care of wounds on the lower extremity. Groups 1 and 2 will receive 4 sham light or treatment sessions, respectively (one session every week for 4 weeks). After these sessions are done, all subjects will continue weekly follow up visits until the wound is closed, or 3 months after the surgery have passed; which ever happens first. One final follow up visit will occur 1 week after the wound closed.

Interventions

DEVICEOmnilux

Photomodulation irradiated with a 633 +/- 3 mm light source for 20 minutes (105 mW/cm, 126 J/cm)

DEVICEOmnilux Sham

Sham light instead of phototherapy from the same light device

Sponsors

University of Miami
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Investigator)

Eligibility

Sex/Gender
ALL
Age
18 Years to 90 Years
Healthy volunteers
No

Inclusion criteria

* Surgical defect on the lower extremity left to heal by secondary intention. * If women of child bearing potential, contraceptive measures should be used * Maximum size of wound is 5cm x5cm; there is no minimum size for the wound.

Exclusion criteria

* History of porphyria photosensitive eruptions, diabetes mellitus, history of venous insufficiency, known history of peripheral arterial disease (ABI \<0.8) * Use of any ointments or creams containing photosensitizers (coumarins or porphyrins) should be discontinued for 2 weeks prior * Use of systemic or local retinoids for the past 6 months. * Current pregnancy or breastfeeding * History of metastatic cancer.

Design outcomes

Primary

MeasureTime frameDescription
Number of Days Required for the Wound to Heal Completely84 daysAssessment by the physician indicating wound closure

Secondary

MeasureTime frameDescription
Change in Relative Area of the Surgical Wound RemainingWeek 1 to Week 2, Week 2 to Week 3, Week 3 to Week 4Initial area \* ((total area in the evaluated week/total area in the first week) \* 100) and reported as a percentage (%)
Change in Total Surface Area of the Surgical WoundWeek 1 to Week 2, Week 2 to Week 3, Week 3 to Week 4, Week 1 to Week 4A blinded investigator manually outlines the wound using a digital planimetry device to measure the surface area in square centimeters.

Countries

United States

Participant flow

Participants by arm

ArmCount
Sham Group (Group 1)
This group will receive 4 sessions of Omnilux sham light, starting 1 week after the surgery. Frequency: 1 session every week (+/- 3 days), for 4 weeks. Session duration: 20 minutes Omnilux sham light
7
Treatment Group (Group 2)
This group will receive 4 treatment sessions with Omnilux 633nm LED, starting 1 week after the surgery. Frequency: 1 session every week (+/- 3 days), for 4 weeks. Session duration: 20 minutes Omnilux: 633nm
7
Total14

Withdrawals & dropouts

PeriodReasonFG000FG001
Overall StudyAdverse Event10
Overall StudyLost to Follow-up02

Baseline characteristics

CharacteristicSham Group (Group 1)Treatment Group (Group 2)Total
Age, Continuous69.3 years
STANDARD_DEVIATION 7.39
72.6 years
STANDARD_DEVIATION 5.41
71.0 years
STANDARD_DEVIATION 6.4
Race and Ethnicity Not Collected0 Participants
Sex: Female, Male
Female
2 Participants4 Participants6 Participants
Sex: Female, Male
Male
5 Participants3 Participants8 Participants

Adverse events

Event typeEG000
affected / at risk
EG001
affected / at risk
deaths
Total, all-cause mortality
0 / 70 / 7
other
Total, other adverse events
3 / 75 / 7
serious
Total, serious adverse events
0 / 70 / 7

Outcome results

Primary

Number of Days Required for the Wound to Heal Completely

Assessment by the physician indicating wound closure

Time frame: 84 days

ArmMeasureValue (MEAN)Dispersion
Sham Group (Group 1)Number of Days Required for the Wound to Heal Completely48.67 daysStandard Deviation 11.1
Treatment Group (Group 2)Number of Days Required for the Wound to Heal Completely63.20 daysStandard Deviation 12.2
Secondary

Change in Relative Area of the Surgical Wound Remaining

Initial area \* ((total area in the evaluated week/total area in the first week) \* 100) and reported as a percentage (%)

Time frame: Week 1 to Week 2, Week 2 to Week 3, Week 3 to Week 4

ArmMeasureGroupValue (MEAN)Dispersion
Sham Group (Group 1)Change in Relative Area of the Surgical Wound RemainingWeek 3 to Week 453.10 Percentage of Wound RemainingStandard Deviation 17
Sham Group (Group 1)Change in Relative Area of the Surgical Wound RemainingWeek 1 to Week 290.80 Percentage of Wound RemainingStandard Deviation 19.4
Sham Group (Group 1)Change in Relative Area of the Surgical Wound RemainingWeek 2 to Week 360.70 Percentage of Wound RemainingStandard Deviation 8.71
Treatment Group (Group 2)Change in Relative Area of the Surgical Wound RemainingWeek 3 to Week 445.98 Percentage of Wound RemainingStandard Deviation 20.5
Treatment Group (Group 2)Change in Relative Area of the Surgical Wound RemainingWeek 1 to Week 296.0 Percentage of Wound RemainingStandard Deviation 23.7
Treatment Group (Group 2)Change in Relative Area of the Surgical Wound RemainingWeek 2 to Week 377.40 Percentage of Wound RemainingStandard Deviation 5.76
Secondary

Change in Total Surface Area of the Surgical Wound

A blinded investigator manually outlines the wound using a digital planimetry device to measure the surface area in square centimeters.

Time frame: Week 1 to Week 2, Week 2 to Week 3, Week 3 to Week 4, Week 1 to Week 4

ArmMeasureGroupValue (MEAN)Dispersion
Sham Group (Group 1)Change in Total Surface Area of the Surgical WoundWeek 1 to Week 2-0.18 Cm^2Standard Deviation 0.57
Sham Group (Group 1)Change in Total Surface Area of the Surgical WoundWeek 2 to Week 3-0.93 Cm^2Standard Deviation 0.82
Sham Group (Group 1)Change in Total Surface Area of the Surgical WoundWeek 3 to Week 4-0.27 Cm^2Standard Deviation 0.6
Sham Group (Group 1)Change in Total Surface Area of the Surgical WoundWeek 1 to Week 4-1.38 Cm^2Standard Deviation 1.03
Treatment Group (Group 2)Change in Total Surface Area of the Surgical WoundWeek 1 to Week 4-1.53 Cm^2Standard Deviation 0.12
Treatment Group (Group 2)Change in Total Surface Area of the Surgical WoundWeek 1 to Week 2-0.25 Cm^2Standard Deviation 0.62
Treatment Group (Group 2)Change in Total Surface Area of the Surgical WoundWeek 3 to Week 4-0.80 Cm^2Standard Deviation 0.34
Treatment Group (Group 2)Change in Total Surface Area of the Surgical WoundWeek 2 to Week 3-0.48 Cm^2Standard Deviation 0.44

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026